POSALLONCT06541067
Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 28 words Show 5 more changesShow less
- Primary completion date changed from estimate of Jan 15, 2027 to Sep 9, 2026
- Study completion moved earlier from Nov 8, 2028 to Jun 2027
- Secondary endpoints: details revised at 12 of 17 entries
- Study description revised
- Site details revised
- Study Identification, Study Status, Oversightv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study completion date: Oct 15, 2028 to Nov 8, 2028
- Start date changed from estimate of Oct 15, 2024 to Nov 8, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Effective residual concentration of posaconazole
Timeframe: On the 8th day of treatment (i.e. after 7 days of treatment)
Secondary (14)
Monitoring of residual plasma concentrations [C]min
Description of circumstances leading to posaconazole underdosing
Description of the reasons for administering posaconazole intravenously (IV)
Description of situations leading to initial non-administration or early discontinuation of posaconazole
Description of invasive fungal infections occurring
Show 9 moreShow less
Description of patient outcome: incidence of engraftment
Description of patient outcome: overall survival (OS)
Description of patient outcome: disease-free survival (DFS)
Description of patient outcome: non-relapse mortality (NRM)
Description of patient outcome: incidence of relapse (IR)
Description of patient outcome: cumulative incidence of acute GVHD
Description of patient outcome: cumulative incidence of chronic GVHD
Description of patient outcome: GVHD-free relapse-free survival (GRFS)
Grade 3 and 4 post-transplant adverse events
Arms and interventions
PosaconazoleExperimental
Drugs: Posaconazole
Sites
1 site in 1 country
- CHU NantesNantes, France